Quantbot Technologies LP Invests $1.35 Million in LeMaitre Vascular, Inc. $LMAT

Quantbot Technologies LP bought a new position in LeMaitre Vascular, Inc. (NASDAQ:LMAT) during the 2nd quarter, HoldingsChannel reports. The fund bought 14,095 shares of the medical instruments supplier’s stock, valued at approximately $1,353,000.

Several other institutional investors have also added to or reduced their stakes in LMAT. Illinois Municipal Retirement Fund grew its holdings in LeMaitre Vascular by 1.1% in the 4th quarter. Illinois Municipal Retirement Fund now owns 11,171 shares of the medical instruments supplier’s stock worth $906,000 after acquiring an additional 123 shares during the last quarter. NewEdge Advisors LLC raised its stake in shares of LeMaitre Vascular by 4.6% during the fourth quarter. NewEdge Advisors LLC now owns 3,158 shares of the medical instruments supplier’s stock valued at $256,000 after acquiring an additional 139 shares during the last quarter. Federated Hermes Inc. raised its stake in shares of LeMaitre Vascular by 0.4% during the second quarter. Federated Hermes Inc. now owns 39,659 shares of the medical instruments supplier’s stock valued at $3,294,000 after acquiring an additional 155 shares during the last quarter. Pictet Asset Management Holding SA boosted its holdings in shares of LeMaitre Vascular by 5.5% during the first quarter. Pictet Asset Management Holding SA now owns 3,259 shares of the medical instruments supplier’s stock worth $356,000 after purchasing an additional 169 shares during the period. Finally, Sound Income Strategies LLC grew its stake in shares of LeMaitre Vascular by 425.6% in the first quarter. Sound Income Strategies LLC now owns 226 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 183 shares during the last quarter. Hedge funds and other institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Price Performance

Shares of LMAT stock opened at $78.97 on Wednesday. The business’s fifty day moving average is $93.85 and its 200 day moving average is $99.56. The company has a quick ratio of 13.96, a current ratio of 16.31 and a debt-to-equity ratio of 0.40. The stock has a market cap of $1.81 billion, a price-to-earnings ratio of 27.71, a PEG ratio of 2.31 and a beta of 0.53. LeMaitre Vascular, Inc. has a twelve month low of $78.29 and a twelve month high of $118.01.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings data on Tuesday, August 4th. The medical instruments supplier reported $0.74 EPS for the quarter, missing the consensus estimate of $0.81 by ($0.07). The firm had revenue of $70.38 million for the quarter, compared to analysts’ expectations of $71.47 million. LeMaitre Vascular had a net margin of 25.02% and a return on equity of 15.63%. The business’s quarterly revenue was up 9.6% compared to the same quarter last year. During the same period in the prior year, the business posted $0.60 EPS. Research analysts expect that LeMaitre Vascular, Inc. will post 2.89 EPS for the current fiscal year.

LeMaitre Vascular Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 3rd. Shareholders of record on Thursday, August 20th will be paid a dividend of $0.25 per share. The ex-dividend date of this dividend is Thursday, August 20th. This represents a $1.00 dividend on an annualized basis and a dividend yield of 1.3%. LeMaitre Vascular’s dividend payout ratio (DPR) is currently 35.09%.

Analyst Ratings Changes

A number of research analysts have commented on the company. Weiss Ratings lowered LeMaitre Vascular from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Friday, August 14th. Citizens Jmp boosted their target price on LeMaitre Vascular from $118.00 to $127.00 and gave the company a “market outperform” rating in a research note on Wednesday, May 6th. Citigroup restated a “market outperform” rating on shares of LeMaitre Vascular in a report on Tuesday, July 21st. Wells Fargo & Company decreased their target price on LeMaitre Vascular from $104.00 to $94.00 and set an “equal weight” rating for the company in a report on Wednesday, August 5th. Finally, Wall Street Zen lowered LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Saturday, August 1st. Three investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, LeMaitre Vascular has a consensus rating of “Hold” and an average target price of $110.60.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.